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S-nitrosylation is a ubiquitous protein modification
emerging as a principal mechanism of nitric oxide
(NO)-mediated signal transduction and cell function.
S-nitrosylases can use NO synthase (NOS)-derived
NO to modify selected cysteines in target proteins.
Despite proteomic identification of over a thousand
S-nitrosylated proteins, few S-nitrosylases have
been identified. Moreover, mechanisms underlying
site-selective S-nitrosylation and the potential role
of specific sequence motifs remain largely unknown.
Here, we describe a stimulus-inducible, heterotri-
meric S-nitrosylase complex consisting of inducible
NOS (iNOS), S100A8, and S100A9. S100A9 exhibits
transnitrosylase activity, shuttling NO from iNOS to
the target protein, whereas S100A8 and S100A9
coordinately direct site selection. A family of proteins
S-nitrosylated by iNOS-S100A8/A9 were revealed by
proteomic analysis. A conserved I/L-X-C-X2-D/E
motif was necessary and sufficient for iNOS-S100A8/
A9-mediated S-nitrosylation. These results reveal an
elusive parallel between protein S-nitrosylation and
phosphorylation, namely, stimulus-dependent post-
translational modification of selected targets by pri-
mary sequence motif recognition.INTRODUCTION
Protein S-nitrosylation is a nitric oxide (NO)-dependent post-
translational modification of cysteine that regulates protein
structure and function in bacteria, plants, and mammals (Naka-
mura et al., 2013; Seth et al., 2012; Yun et al., 2011). An
activated NO moiety is covalently added to the free thiol group
on cysteine, generating an S-nitrosothiol. High-throughput
proteomic approaches have identified more than a thousand
S-nitrosylated (SNO-) proteins and linked to diverse cellular
functions (Doulias et al., 2010; Seth and Stamler, 2011). Physi-
ological S-nitrosylation contributes to cellular homeostasis,
whereas, dysregulation can lead to severe pathological conse-quences (Haldar and Stamler, 2013; Lim et al., 2008a; Naka-
mura et al., 2013).
Like phosphorylation and ubiquitination, protein S-nitrosy-
lation is regulatable, reversible, and target and site selective.
However, the mechanism underlying selectivity has remained
elusive. The eukaryotic nitric oxide synthase (NOS) family has
three cell-selective isoforms, neuronal NOS (nNOS), inducible
NOS (iNOS), and endothelial NOS (eNOS). There is limited evi-
dence that NOS can mediate selective S-nitrosylation via direct
NOS-substrate interactions (Fang et al., 2000; Garcı´a-Carden˜a
et al., 1998; Kim et al., 2005); however, thismechanism is unlikely
to account for selective targeting of Cys residues in a multitude
of distinct protein substrates by only three NOS isoforms. An
alternative adaptor mechanism is supported by reports that
certain SNO-proteins have S-nitrosylase activity and can trans-
fer NO from its own S-nitrosothiol group to a free thiol on a target
protein via direct protein-protein interaction. Fewer than ten
S-nitrosylases have been identified to date (Nakamura and Lip-
ton, 2013), and the primary sequences and structures that estab-
lish the rules governing specificity of substrate recognition and
cysteine transnitrosylation are largely unknown. Recent global
analyses of S-nitrosocysteine sites revealed information on
specific determinants of S-nitrosylation, but failed to identify a
primary sequencemotif for site-selective S-nitrosylation (Doulias
et al., 2010; Hao et al., 2006; Marino and Gladyshev, 2010).
Together, these findings suggest that additional S-nitrosylases,
mechanisms, and motifs are yet to be revealed.
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) is
a key glycolytic enzyme and a well-studied S-nitrosylation
target. S-nitrosylation of GAPDH regulates enzymatic activity
(Padgett and Whorton, 1995), but also mediates several
‘‘moonlighting’’ functions (Jia et al., 2012; Kornberg et al.,
2010). Recently, we reported that selective, inducible S-nitrosy-
lation of GAPDH dysregulates translational control of gene
expression by the interferon-gamma (IFN-g)-activated inhibitor
of translation (GAIT) complex (Jia et al., 2012). GAPDH, along
with ribosomal protein L13a, Glu-Pro tRNA synthetase
(EPRS), and NS1-associated protein are induced by IFN-g to
form the GAIT complex (Sampath et al., 2004) that inhibits
translation of vascular endothelial growth factor-A (VEGF-A)
and other inflammation-related mRNAs (Ray et al., 2009;
Vyas et al., 2009). Low-density lipoprotein (LDL) that is oxida-
tively-modified (LDLox) by the physiological myeloperoxidaseCell 159, 623–634, October 23, 2014 ª2014 Elsevier Inc. 623
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Figure 1. iNOS Is Essential for Cys247
S-Nitrosylation
(A) L-NMMA suppresses GAPDH Cys247 S-nitro-
sylation. Human PBM were transfected with
HA-GAPDH (WT and Cys-to-Ser mutant). Cells
were preincubated for 1 hr with L-NMMA (500 mM)
and then treated for 24 hr with IFN-g (500 U/ml)
plus LDLox (25 mg/ml). Lysates were subjected
to immunoprecipitation (IP) and immunoblot
(IB) with antibodies indicated. S-nitrosylation was
determined by biotin-switch (Biot.-sw).
(B) NOS inhibitors block GAPDH S-nitrosyla-
tion. PBM were preincubated with L-NMMA or
1400W (100 mM), and then with LDLox/IFN-g.
Lysates were subjected to IP and IB or Biot.-sw.
analysis.
(C) IFN-g plus LDLox induce iNOS expression in
human PBM. Protein and mRNA were determined
by IB and qRT-PCR respectively. iNOS expression
was normalized to b-actin (mean ± SEM, n = 3
experiments).
(D) iNOS is required for inducible GAPDH S-ni-
trosylation. iNOS was depleted by siRNA treat-
ment. Lysates from agonist-treated iNOS-defi-
cient and control cells were subjected to IB and IP
or Biot.-sw. analysis.
(E) LDLox/IFN-g induces iNOS-GAPDH interaction.
PBM were incubated for 24 hr with different
agonist. Lysates were subjected to IP and IB with
indicated antibodies.
(F) LDLox induces iNOS-GAPDH interaction. U937
cells were transfected with His-iNOS or empty
vector, and then treated with 25 mg/ml native LDL
or LDLox. Lysates were subjected to IP and IB with
indicated antibodies.
(G) iNOS expression is not sufficient for GAPDH
S-nitrosylation. U937 cells were transfected with
His-iNOS. Lysates from control and treated cells
were subjected to IP and IB with indicated anti-
bodies or Biot.-sw. analysis.
(H) Inducible GAPDH S-nitrosylation and L13a
degradation are iNOS dependent. BMDM from
wild-type or iNOS/ mice were treated with IFN-g, LDLox, or both. Lysates were subjected to IP and IB with indicated antibodies or Biot.-sw. analysis.
(I) iNOS contributes to GAIT pathway dysregulation. BMDM from iNOS/ (top 3 panels) or WT mice (bottom 3 panels) were stimulated for up to 24 hr and then
subjected to 35S-Met/Cys metabolic labeling. Lysates were subjected to IP with anti-VEGF-A, -Cp, or -b-actin antibodies, and labeling determined by elec-
trophoresis and autoradiography.(MPO) system suppresses GAIT system activity by selective
S-nitrosylation of GAPDH Cys247, a residue distant from the
catalytic domain. S-nitrosylated GAPDH fails to bind and protect
L13a, leading to ubiquitination and proteasomal degradation of
L13a and consequent GAIT system inactivation. Here, we eluci-
date the molecular mechanism underlying stimulus-dependent,
site-selective S-nitrosylation of GAPDH, revealing an inducible
heterotrimeric S-nitrosylase complex and a consensus motif
that directs specific S-nitrosylation on multiple target proteins.
RESULTS
iNOS Is Required for LDLox/IFN-g-Inducible
S-Nitrosylation of GAPDH Cys247
To determine the role of enzymatically generated NO in
GAPDH S-nitrosylation, NOS inhibitors were used. Human624 Cell 159, 623–634, October 23, 2014 ª2014 Elsevier Inc.peripheral blood monocytes (PBM) were transfected with HA-
tagged GAPDH (HA-GAPDH) plasmids bearing Cys-to-Ser
mutations at each of the three Cys residues, or wild-type. Cells
were then incubated with IFN-g and LDLox for 24 hr in the pres-
ence of the nonselective NOS inhibitor, L-NMMA (NG-mono-
methyl-L-arginine acetate). The biotin-switch assay revealed
specific S-nitrosylation of GAPDH at Cys247 and suppression
by L-NMMA (Figure 1A). Also, GAPDH S-nitrosylation was
completely suppressed by 1400W (Figure 1B), which exhibits
a 1,000-fold selectivity for iNOS, the principal myeloid cell
isoform (Garvey et al., 1997; Hara et al., 2005). IFN-g and
LDLox markedly induced iNOS mRNA and protein in PBM;
however, the individual agonists were only modestly stimu-
latory (Figure 1C). iNOS-specific siRNA blocked iNOS induc-
tion and GAPDH S-nitrosylation supporting its critical role
(Figure 1D).
LDLox/IFN-g Induces iNOS and Its Interaction
with GAPDH
In addition to functioning as the major NO source, NOS isoforms
can direct selective S-nitrosylation by interaction with targets.
LDLox/IFN-g, but not with LDL/IFN-g or IFN-g alone, induced
the binding of iNOS to GAPDH (Figure 1E). To determine the spe-
cific role of LDLox in the iNOS-GAPDH interaction, U937 cells
were transfected with His-tagged iNOS and then treated with
LDLox for 24 hr in absence of IFN-g. LDLox by itself was sufficient
to induce protein interaction, thus revealing a dual function of
LDLox in both iNOS induction and interaction with GAPDH (Fig-
ure 1F). To determine whether iNOS by itself is sufficient for
GAPDH S-nitrosylation, cells were transfected with His-iNOS
but S-nitrosylation was not observed in the absence of LDLox/
IFN-g, indicating iNOS is necessary but not sufficient for modifi-
cation (Figure 1G).
Dysregulation of GAIT System by LDLox/IFN-g
Requires iNOS
To establish the role of iNOS in GAPDH S-nitrosylation and L13a
degradation, bone marrow-derived macrophages (BMDM) iso-
lated from iNOS/ and wild-type mice were incubated with
IFN-g or LDLox or both. LDLox/IFN-g-inducible S-nitrosylation
of GAPDH was observed in BMDM from wild-type but not iN-
OS/ mice (Figure 1H). Likewise, GAPDH-L13a interaction
was not inhibited by LDLox/IFN-g in iNOS
/ BMDM, subse-
quently preventing L13a degradation. Finally, we investigated
the role of iNOS/ in GAIT system inactivation by LDLox/IFN-g
that prevents delayed translational silencing of GAIT element-
bearing target mRNAs, e.g., VEGF-A and ceruloplasmin (Cp),
thereby prolonging their expression (Jia et al., 2012). Synthesis
of VEGF-A and Cp in agonist-treated BMDM was determined
by 35S-Met metabolic labeling. BMDM from wild-type mice ex-
hibited translational silencing after 24 hr of IFN-g treatment
that was prevented by LDLox (Figure 1I). Likewise, expression
of GAIT targets was silenced by IFN-g in BMDM from iNOS/
mice. However, LDLox failed to prevent the inhibition, consistent
with a critical role of iNOS-driven S-nitrosylation of GAPDH in
regulating GAIT system activity.
S100A8/9 Complex Mediates Binding of iNOS to GAPDH
Human GAPDH is a multifunctional protein containing Cys
residues at 152, 156, and 247. LPS-stimulated S-nitrosylation
of GAPDH Cys152 contributes to its role in apoptotic signaling
and heme trafficking (Chakravarti et al., 2010; Hara et al.,
2005), whereas LDLox/IFN-g-stimulated S-nitrosylation of
Cys247 prevents GAIT system activation (Jia et al., 2012). Like
Cys247 S-nitrosylation, iNOS is essential for Cys152 S-nitrosyla-
tion as well (Hara et al., 2005). However, in neither case is the
mechanism of selective S-nitrosylation known. Differential nitro-
sylation of distinct sites by iNOS suggests potential recruitment
of other proteins to provide site selectivity. To identify interacting
proteins, lysates from LDLox/IFN-g-treated PBM were immuno-
precipitated with anti-iNOS or anti-GAPDH antibody and
resolved by electrophoresis and silver stain (Figure 2A). Proteins
in enriched bands were identified by liquid chromatography-tan-
demmass spectrometry (LC-MS/MS) (Table S1 available online).
Two proteins, histone H2A and S100A9, were captured by bothantibodies. However, immunoblot analysis failed to show an
interaction between H2A and iNOS or GAPDH (Figure S1).
S100A9 is an inflammatory mediator that forms a heterodimeric
complex with S100A8 in myeloid cells (Roth et al., 2003).
Notably, S100A8 was also detected by LC-MS (Table S1).
Detection of iNOS and GAPDH, as positive controls, validated
the approach. LDLox/IFN-g did not induce expression of
S100A8 or S100A9 (Figure 2B), but led to the inducible assembly
of a complex containing all four proteins (Figure 2C). In the
absence of stimulation, only S100A8 and S100A9 were found
to interact.
We used a knockdown approach to determine whether
S100A8 and S100A9 are necessary for interaction of the NO
donor, iNOS, with its target, GAPDH. Depletion of GAPDH did
not disrupt iNOS binding to S100A8/A9, and S100A8 depletion
did not block the interaction of the other three components
(Figure 2D, left). However, S100A9 depletion prevented the
binding of iNOS to GAPDH and S100A8, suggesting S100A9
is an indispensable intermediary for iNOS interaction with
its S-nitrosylation target, GAPDH (Figure 2D, right). To deter-
mine the specific stimulus-dependence of iNOS binding to
S100A8/A9, PBM were transfected with His-iNOS. LDLox by
itself, but not IFN-g, was sufficient to induce the interaction
of iNOS with S100A8/A9 (Figure 2E). Because LDLox induces
Ca2+ flux in leukocytes (van Tits et al., 2000) and both
S100A8 and S100A9 are Ca2+-binding proteins (Hessian
et al., 1993), we investigated the role of Ca2+ in complex
assembly. In PBM ectopically expressing His-iNOS, LDLox
induced a 2.9-fold increase in cytosolic Ca2+, iNOS binding
to S100A8/A9 and GAPDH S-nitrosylation (Figure 2F). Ca2+
chelators BAPTA-AM or EGTA suppressed Ca2+ induction
by LDLox and inhibited iNOS-S100A8/A9 complex assembly
and GAPDH S-nitrosylation. Ca2+ ionophores A23187 and
ionomycin raised intracellular Ca2+ to levels comparable to
LDLox-treated cells, but did not induce complex assembly, sug-
gesting Ca2+ is necessary but not sufficient for LDLox-induced
S-nitrosylation.
Transnitrosylase Activity of S100A9 Is Essential
for GAPDH Cys247 S-Nitrosylation
S100A9 knockdown prevented inducible GAPDH S-nitrosyla-
tion, whereas S100A8 knockdown was ineffective, indicating
S100A9 is essential for GAPDH S-nitrosylation (Figure 3A).
We investigated the hypothesis that S100A9 not only mediates
iNOS-GAPDH interaction, but also acts as a functional couple,
transferring iNOS-derived NO to its target. LDLox/IFN-g
induced iNOS-dependent S-nitrosylation of S100A9 in PBM
(Figure 3B). We considered the possibility that SNO-S100A9
acts as an S-nitrosylase, transferring the NO moiety to GAPDH.
Purified S100A9 protein was subjected to in vitro S-nitrosyla-
tion by GSNO or GSH as negative control. After desalt,
GSNO-modified S100A9 was incubated with purified GAPDH
protein. GSNO led to S-nitrosylation of S100A9 that in turn
induced GAPDH S-nitrosylation (Figure 3C). We determined
the requirement for Cys3, the sole cysteine in human S100A9,
for transnitrosylase activity. Endogenous S100A9 expression
in PBM was silenced by 30UTR-specific siRNA and replenished
by cotransfection with myc-S100A9, wild-type or C3A mutant.Cell 159, 623–634, October 23, 2014 ª2014 Elsevier Inc. 625
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Figure 2. S100A8/A9 Directs iNOS-GAPDH
Interaction and GAPDH S-Nitrosylation
(A) S100A8 and S100A9 identified as binding
partners of iNOS and GAPDH. PBM were incu-
bated for 24 hr with LDLox/IFN-g. Lysates were
subjected to IP with anti-iNOS or anti-GAPDH
antibodies, or control IgG, and analyzed by elec-
trophoresis and silver stain. Specific bands were
identified by LC-MS analysis.
(B) LDLox/IFN-g does not induce S100A8 or
S100A9 expression. Lysates from treated PBM
were subjected to IB analysis with antibodies
indicated.
(C) LDLox/IFN-g induces assembly of iNOS-
S100A8/A9-GAPDH complex. Lysates from
treated PBM were subjected to IP and IB analysis
with antibodies indicated.
(D) S100A9 facilitates binding of S100A8 and
GAPDH to iNOS. PBM were transfected with
siRNA targeting S100A8, S100A9, or GAPDH. Af-
ter LDLox/IFN-g treatment, lysates from treated
cells were IP with anti-iNOS antibody and sub-
jected to IB with antibodies indicated (left). Protein
interaction model is shown (right).
(E) LDLox inducesbindingofS100A8andS100A9 to
iNOS. PBM were transfected with His-iNOS. After
recovery, cells were treated with IFN-g, LDLox, or
both; lysates from treated PBM were subjected to
IP and IB analysis with antibodies indicated.
(F) LDLox-stimulated intracellular Ca
2+ is required
for iNOS-S100A8/A9 complex assembly and ac-
tivity. PBM that ectopically expressed His-iNOS
were treated with LDLox in the presence of calcium
chelators 15 mM BAPTA-AM or 2 mM EGTA, or
with calcium ionophores 5 mM A23187 or 1 mM
ionomycin. Lysates were subject to IP and IB with
indicated antibodies or Biot.-sw. analysis. Cyto-
solic calcium was determined with o-cresolph-
thalein at 575 nm, and normalized to total cyto-
solic protein (mean ± SEM, n = 5 experiments).
See also Figure S1 and Table S1.S100A9 S-nitrosylation was abolished by S100A9 knockdown,
as was GAPDH S-nitrosylation. Recombinant wild-type
S100A9, but not C3A mutant, restored GAPDH S-nitrosylation,
verifying the critical role of Cys3 (Figure 3D). In addition,
S100A9 knockdown rescued L13a from inducible degradation
and restored GAIT-directed suppression of VEGF-A, establish-
ing the link between S100A9 and translational control by the
GAIT system. LDLox/IFN-g induced S-nitrosylation of wild-
type S100A9 and binding to both iNOS and S100A8 (Figure 3E).
The C3A mutant interacted with S100A8 but failed to bind
iNOS, suggesting Cys3 S-nitrosylation is required for complex
assembly, consistent with an important role of S-nitrosylation
in protein interaction as described previously (Hess et al.,
2005; Marozkina and Gaston, 2012).626 Cell 159, 623–634, October 23, 2014 ª2014 Elsevier Inc.S100A8 Contributes to Site
Selectivity of S-Nitrosylase Complex
in GAPDH S-Nitrosylation
In contrast to S100A9, S100A8 depletion
did not disrupt the iNOS-GAPDH inter-
action or prevent GAPDH S-nitrosyla-tion (Figures 2D and 3A). We considered the possibility that
S100A8 contributes to target specificity of S-nitrosylation.
PBM were cotransfected with S100A8 siRNA and HA-GAPDH.
Control cells treated with scrambled siRNA exhibited specific
stimulus-inducible S-nitrosylation of GAPDH Cys247 as shown
by the total absence of modification of the C247S mutant (Fig-
ure 4A). Remarkably, S100A8 knockdown permitted S-nitrosyla-
tion of C247S mutant indicating a loss of target specificity and
suggests that S100A8 directs site selectivity of the iNOS-
S100A8/A9 S-nitrosylase complex. S100A8 depletion permitted
S-nitrosylation of GAPDH Cys247 and Cys152, but not Cys156
(Figure 4B).
To elucidate the mechanism of S100A8-directed site-selec-
tion, the interaction of S100A8 and GAPDH was probed by
A D
B
C
E
Figure 3. Transnitrosylase Activity of
S100A9 Directs iNOS-S100A8/A9 Complex
Assembly and GAPDH S-Nitrosylation
(A) S100A9 is essential for inducible GAPDH S-
nitrosylation. PBM were transfected with siRNA
against S100A8 or S100A9 (or scrambled), and
then treated with LDLox/IFN-g for 24 hr. Lysates
were subjected to IP and IB as indicated. GAPDH
S-nitrosylation was determined by Biot.-sw.
(B) LDLox/IFN-g induces S-nitrosylation of S100A9.
PBM were preincubated with L-NMMA or 1400W,
and then with LDLox/IFN-g. S100A9 S-nitrosylation
was determined by Biot.-sw. assay.
(C) SNO-S100A9 S-nitrosylates GAPDH in vitro.
Recombinant GAPDH protein was incubated with
His-S100A9 pretreated in vitro with 100 mM GSH
or GSNO, or GSNO-desalted buffer as control.
S-nitrosylation was determined by Biot.-sw. assay.
(D) GAPDH S-nitrosylation requires Cys3 of
S100A9. PBM were cotransfected with S100A9
30-UTR-targeting siRNA and recombinant WT
myc-S100A9 or C3A mutant. Lysates from treated
PBM were subjected to IB with indicated anti-
bodies or Biot.-sw. analysis.
(E) S100A9 Cys3 is critical for iNOS-S100A9 inter-
action. PBM were transfected with recombinant
myc-S100A9 (WT or C3A), and then treated with
LDLox/IFN-g. Lysates from treated cells were
subjected to IP and IB with indicated antibodies
or Biot.-sw. analysis.His-tag pull-down. Purified GAPDH specifically bound recombi-
nant human S100A8, but not EPRS WHEP-R1 control protein
(Jia et al., 2008) (Figure 4C). The GAPDH region that interacts
with S100A8 was probed using the FeBABE (Fe(III) (s)-1-(p-
bromoacetamidobenzyl) EDTA) ‘‘artificial protease’’ method.
The sole cysteine in S100A8, Cys42, was mutated to serine,
and cysteine residues were introduced into S100A8 at ten
amino acid intervals for covalent labeling with FeBABE. The
site of interaction between HA-GAPDH and FeBABE-labeled
S100A8 was detected by FeBABE-directed, hydroxyl radical-
mediated cleavage mapping. Wild-type S100A8 and three
mutants (I22C/C42S, D32C/C42S, and D52C/C42S) caused
marked cleavage of GAPDH in helices a1 and a3 (Figure 4D).
Importantly, GAPDH Cys247 is located near the termini of both
helices, suggesting S100A8 may contribute to specific GAPDH
S-nitrosylation by proximity to the target cysteine (Figure 4E),
possibly by altering the nearby structure. We applied Fo¨rster
resonance energy transfer (FRET) to probe the S100A8-induc-
ible conformational shift. GAPDH Cys156 was mutated to Ser
to generate a FRET donor-acceptor pair of Cys152 and Cys247
for dye labeling. GAPDH C156S was labeled with mixed thiol-
reactive dyes, Alexa 546- and 647-C5-maleimide. The apparent
mean interfluor distance for GAPDH by itself was calculated
to be 51.6 A˚ and increased to 58.0 A˚ by addition of S100A8
(Figure S2), indicative of a substantial conformational shift,
consistent with S-nitrosylation of tetrameric GAPDH as the
X-ray structure (Ismail and Park, 2005) indicates the distancebetween the Cys-Cys pair in the monomer is 21 A˚, whereas
the maximum distance in the tetramer is 64.8 A˚ (Ismail and
Park, 2005).
iNOS-S100A8/A9 Directs Selective S-Nitrosylation
of Multiple Targets
We applied a global, proteomic approach to assess whether
iNOS-S100A8/A9 nitrosylates other proteins. S100A9-depleted
or untreated human PBM were incubated with LDLox/IFN-g for
24 hr, and S-nitrosylated proteins in lysates were subjected
to biotin-switch labeling and streptavidin-agarose pulldown.
Following electrophoresis and Coomassie blue stain, bands
identified in untreated, but not in S100A9-depleted cells, were
selected for LC-MS analysis, and an ensemble of 95 SNO-pro-
tein candidates, including GAPDH and S100A9, were identified
(Table S2).
LDLox/IFN-g-inducible S-nitrosylation was determined for
candidates having only one or two cysteines, thereby facilitating
detailed analysis. Five of the nine candidates, annexin V, ezrin,
HSPA5, moesin, and vimentin, exhibited robust, stimulus-induc-
ible S-nitrosylation (Figure 5A, left). 1400W inhibited S-nitrosy-
lation of all five candidates, indicating the requirement for
iNOS. Four candidates were not S-nitrosylated indicating
either false-positive LC-MS results, or possibly coprecipitation
with S-nitrosylated interacting partners (Figure 5A, right).
S100A9-depletion suppressed S-nitrosylation of annexin V,
ezrin, moesin, and vimentin (Figure 5B). Unexpectedly, HSPA5Cell 159, 623–634, October 23, 2014 ª2014 Elsevier Inc. 627
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Figure 4. S100A8 Determines Site Selec-
tivity of the iNOS-S100A8/A9 S-Nitrosylase
Complex
(A) S100A8 directs selective S-nitrosylation of
GAPDH. PBM were cotransfected with S100A8-
specific siRNA andHA-GAPDH (WTor C247S), and
then treated with LDLox/IFN-g for 24 hr. Cell lysates
were subjected to IP and IB as shown. Protein
S-nitrosylation was determined by Biot.-sw.
(B) S100A8 depletion leads to inducible GAPDH
S-nitrosylation on Cys152 and Cys247. PBM were
transfected with HA-GAPDH (WT or C247S), or
cotransfected with both S100A8 siRNA and HA-
GAPDH Cys-to-Ser mutants as indicated. Cells
were then treated with LDLox/IFN-g. Lysates were
subjected to IP and IB or Biot.-sw.
(C) S100A8 by itself binds GAPDH. Purified His-
S100A8 and His-EPRS WHEP-R1 protein (as con-
trol) were incubatedwithGAPDHseparately. Protein
interaction was determined by IP with anti-His-tag
antibody and IB with antibodies as indicated.
(D) Fe-BABE determination of S100A8 binding
sites on GAPDH. FeBABE-labeled S100A8 bearing
cysteine mutations at 10-amino acid intervals in
the context of a C42S mutation was incubated
with purified N terminus, HA-GAPDH. Cleavage
fragments were determined by IB with anti-HA-
tag antibody. Purified recombinant GAPDH and
S100A8 proteins were determined by SDS-PAGE
and Coomassie blue stain.
(E) Structural model of S100A8 binding domain of
GAPDH. GAPDH a helices a1 and a3 (carmine),
and Cys247, Cys156, and Cys152 (yellow spheres)
are indicated.
See also Figure S2.S-nitrosylation was not affected by S100A9 depletion indicative
of modification by an S100A9-independent S-nitrosylase.
The possibility that a specific motif directs modification by
iNOS-S100A8/A9 was explored by sequence alignment. 21
amino acids surrounding all seven cysteine residues in five
validated target SNO-proteins (ezrin and moesin each contain
two cysteines) were aligned. A conserved I/L-X-C-X2-D/E
sequence is present at Cys247 in GAPDH, in the two validated
SNO-proteins containing a single cysteine, and in one of
two cysteines in the other two validated proteins, but not in
the nonvalidated proteins or at Cys152 or Cys156 in GAPDH
(Figure 5C).
S-Nitrosylation Motif Directs Selective Target
Recognition by iNOS-S100A8/A9
The function of the putative sequence motif was tested in
GAPDH. Cys152 and Cys156 were mutated to Ser to restrict anal-
ysis to Cys247. Site-directed mutagenesis of Leu245 or Glu250, or
both, in the consensus motif markedly abrogated LDLox/IFN-g-
inducible S-nitrosylation of GAPDH at Cys247 (Figure 6A, top).
GSNO induced S-nitrosylation of wild-type and all mutant
GAPDH isoforms equally showing a complete absence of
target-specific S-nitrosylation by GSNO (Figure 6A, bottom).
To characterize the role of S100A8 inmotif recognition,S-nitrosy-
lation of motif mutants was assessed in S100A8-deficent
cells. Unexpectedly, S100A8 depletion restored inducible628 Cell 159, 623–634, October 23, 2014 ª2014 Elsevier Inc.S-nitrosylation of Cys247 in the Leu245 mutant, but not in the
Glu250 or doublemutant, suggesting Leu245 is necessary formotif
recognition byS100A8andGlu250 is recognizedby iNOS/S100A9
(Figure 6B). The GAPDH crystal structure indicates surface-
accessibility of the three motif residues (Figure 6C).
To explore motif universality, the SNO-site of human moesin
was investigated. Cys117 and Cys284 were individually mutated
to Ser. LDLox/IFN-g was unable to induce S-nitrosylation of
C117S moesin indicating Cys117 is the sole S-nitrosylation site
(Figures 6D and 6E, left). In contrast to the loss of target speci-
ficity observed for GAPDH, depletion of S100A8 did not alter
S-nitrosylation site selection in moesin, suggesting a possible
steric constraint prevents transfer of the NO moiety (Figures
6E, left, and 6F). Cys117 is within a predicted S-nitrosylation
motif with Ile115 and Glu120. As expected, LDLox/IFN-g induced
S-nitrosylation of wild-type moesin and the C284S mutant,
but not motif-negative mutants containing I115M or E120M,
or both (Figure 6E, right, and 6G). S100A8 depletion restored
S-nitrosylation of Ile115 mutant, however, the Glu120 mutation still
blocked S-nitrosylation of moesin (Figure 6H). Consistent with
GAPDH motif recognition, this result suggests a general rule in
which the I/L residue is recognized by S100A8 and D/E is critical
for S-nitrosylation by iNOS/S100A9 (Figure 7A). Together these
experiments show that both the upstream and downstream
components of the I/L-X-C-X2-D/E motif are required for LDLox/
IFN-g induced S-nitrosylation.
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Figure 5. Global S-Nitrosylation by the
iNOS-S100A8/A9 Complex
(A) iNOS-dependent S-nitrosylation of candidates.
PBM were preincubated with 1400W, and then
with LDLox/IFN-g. S-nitrosylated (left) and non-S-
nitrosylated (right) candidates were determined
by Biot.-sw. assay and by IB with antibodies as
indicated.
(B) S100A9-dependent S-nitrosylation of candi-
dates. PBM were transfected with S100A9 (or
scrambled) siRNA, and then treated with LDLox/
IFN-g. S-nitrosylation of iNOS-dependent candi-
dates was determined by Biot.-sw. Protein ex-
pression was determined IB with antibodies
indicated.
(C) Identification of a putative S-nitrosylation
consensus sequence in iNOS-S100A8/A9-S-ni-
trosylated proteins. Sequences ten amino acids
upstream and downstream from every cysteine in
five validated SNO-proteins and 12 sites in six
proteins found to be not S-nitrosylated were
aligned by Clustal X. Residues conforming to the
consensus motif are boxed.
See also Table S2.To determine whether the motif is sufficient for S-nitrosylation,
a gain-of-function approach was explored using moesin as
target. We observed that the Cys117-containing motif is surface
accessible and near the terminus of an a helix. As a target
we selected a nearby surface accessible site near the terminus
of a nearby a helix (H161-X-L163-X2-D
166) (Figure 6E, right).
To eliminate background S-nitrosylation, Cys117 and Cys284
were mutated to serine. The endogenous H161-X-L163-X2-D
166
sequence was mutated stepwise to generate I161-X-C163-X2-
E166, which conforms to the consensus S-nitrosylation motif.
Moesin with a Cys residue inserted by an L163C mutation failed
to be S-nitrosylated by LDLox/IFN-g treatment (Figure 6I).
However, the H161I/L163C double mutant was efficiently
S-nitrosylated. Likewise, a H161I/L163C/D166E triple mutant
was modified revealing a similar effectiveness of Asp and Glu.
DISCUSSION
S-nitrosylation has emerged as a dominant regulatory mecha-
nism in NO-associated signal transduction and cell function
(Gould et al., 2013; Smith and Marletta, 2012). More than 3,000
S-nitrosocysteine sites have been identified by proteomicCell 159, 623–634analysis of in vitro and in vivo S-nitrosy-
lated proteins (Chen et al., 2010). Despite
the extreme diversity, the apparent fidelity
and site-selective nature of the modifica-
tion suggests precise regulation of the
S-nitrosylation process (Seth and Stamler,
2011). Using biochemical and genetic
approaches, we have identified a stim-
ulus-activated S-nitrosylase complex that
directs motif-dependent protein S-nitro-
sylation in human myeloid cells (Figure 7).
IFN-g and LDLox synergistically induceiNOS expression and initiate the assembly of a S-nitrosylase
complex consisting of iNOS and S100A8/A9. LDLox-inducible
interaction of iNOS to S100A8 and S100A9, both calcium-bind-
ing proteins, is accompanied by induction of intracellular Ca2+,
which may be mediated by the CD36 receptor and the Lyn/
Fyn-Vav signaling pathway (Rahaman et al., 2011). Although
S100A8 S-nitrosylated in vitro by GSNO can slowly transfer
the NO group to hemoglobin (Lim et al., 2008b), the function of
intracellular S100A8/A9 in S-nitrosylation has not been inves-
tigated. In our studies, we show that S100A9 acts both as an
adaptor linking iNOS to its target via protein-protein interaction
and as a transnitrosylase that transfers the NO moiety from
iNOS to its target, via its own S-nitrosylated Cys3. S100A8 inter-
acts with the target and dictates site-specificity of the S-nitrosy-
lase complex by motif recognition. S100A8 binding induces a
conformational change in the target protein and restricts transfer
of NO from S100A9 to the motif-associated cysteine.
All three NOS isoforms act as NO donors for target-selective
S-nitrosylation in vivo (Seth and Stamler, 2011). Importantly,
individual NOS isoforms can direct selective S-nitrosylation of
distinct cysteine residues in the same protein. In one well-stud-
ied example, iNOS induces GAPDH S-nitrosylation at either, October 23, 2014 ª2014 Elsevier Inc. 629
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Figure 6. [I/L]-X-C-X2-[D/E] Motif Is Neces-
sary and Sufficient for iNOS-S100A8/A9-
Directed Protein S-Nitrosylation
(A) GAPDH Leu245 and Glu250 are critical for S-ni-
trosylation of Cys247. PBM were transfected with
HA-GAPDH (WT and mutant). Cells were then
incubated with LDLox/IFN-g (top two panels) or
1 mM GSNO (lower two panels). Cell lysates were
subjected to IP and IB as indicated; protein S-ni-
trosylation was determined by Biot.-sw.
(B) S100A8 directs motif recognition in GAPDH S-
nitrosylation. PBM were transfected with HA-
GAPDH (WT or C247S), or cotransfected with
S100A8 siRNA and HA-GAPDH mutant. Cell ly-
sates were subjected to IP and IB with antibodies
indicated. Protein S-nitrosylation was determined
by Biot.-sw.
(C) Structural model of S-nitrosylation motif in
human GAPDH. Leu245 (blue), Cys247 (green), and
Glu250 (red) are highlighted.
(D) Identification of S-nitrosylation site in moesin.
PBM were transfected with HA-moesin (WT or
Cys-to-Ser mutant). After recovery, cells were
treated with LDLox/IFN-g for 24 hr and S-nitro-
sylation of HA-moesin determined by Biot.-sw.
assay.
(E) Structural model of human moesin highligh-
ting both cysteine residues and S-nitrosylation
motif. Left: localization of moesin Cys residues.
Ile115 (blue), Cys117 (green), Glu120 (red) and
Cys284 (purple) are highlighted. Right: model of
endogenous and synthetic S-nitrosylation motifs
in moesin. Ile115 (blue), Cys117 (green) and Glu120
(red) in the conserved motif are highlighted, as
are residues mutated in the gain-of-function
study, His161 (blue), Leu163 (green) and Asp166
(red).
(F) Absence of S100A8 does not alter moesin S-
nitrosylation site. PBM were transfected with HA-
moesin (WT or mutant), or cotransfected with both
S100A8 siRNA and mutated HA-moesin. After
recovery, cells were treated with LDLox/IFN-g for
24 hr. Lysates from treated cells were subjected to
IP and IB with antibodies indicated; S-nitrosylation
was determined by Biot.-sw.
(G) Ile115 and Glu120 are critical for Cys117 S-ni-
trosylation of moesin. PBM were transfected with
HA-moesin (WT or mutant). After recovery, cells
were treated with LDLox/IFN-g (top 2 panels) or GSNO (lower 2 panels), and S-nitrosylation of HA-moesin determined by Biot.-sw.
(H) S100A8 recognizes S-nitrosylation motif of moesin. PBM were transfected with HA-moesin (WT or C117S), or cotransfected with both S100A8 siRNA and
HA-moesin mutant. Lysates from treated cells were subjected to IP and IB as indicated; S-nitrosylation was determined by Biot.-sw.
(I) Gain-of-function analysis of S-nitrosylation motif in moesin. PBM were transfected with HA-moesin (WT or mutant), and then treated with LDLox/IFN-g. Cell
lysates were subjected to IP and IB as indicated. S-nitrosylation was determined by Biot.-sw.Cys152 (Hara et al., 2005) or Cys247 (Figure 1) in distinct cell types
and in response to distinct stimuli, most clearly illustrating both
high-level specificity as well as the utilization of multiple mecha-
nisms. The recognition of amultitude of targets by just three NOS
isoforms distinguishes S-nitrosylation from phosphorylation, a
site-specific posttranslational modification mediated by 950
human kinases (Buzko and Shokat, 2002). Multiple adaptor pro-
teins might contribute to the specificity problem of substrate
recognition by NOS isoforms. Supporting this mechanism,
PSD-95 (Lipton et al., 2002) and CAPON (Fang et al., 2000) act630 Cell 159, 623–634, October 23, 2014 ª2014 Elsevier Inc.as scaffolds that direct nNOS binding to its S-nitrosylation
targets. This mechanism is analogous to the polyubiquitination
system in which one of520 E3 ubiquitin ligases act as adaptors
to direct binding of the catalytic E2 ubiquitin-conjugating
enzymes that transfer ubiquitin to the target lysine residue
(Li et al., 2008). The adaptor mechanism in site-selective S-nitro-
sylation is supported by our finding that S100A8/A9 directs the
binding of iNOS to GAPDH. However, S100A8/A9 also exhibits
transnitrosylase activity, transferring the NO group from the
iNOS donor to GAPDH, as well as to four other validated targets
AB
Figure 7. Schematic of iNOS-S100A8/A9-
Directed, Site-Selective S-Nitrosylation
(A) S100A8 and S100A9 coordinately direct target-
selective S-nitrosylation by recognition of [I/L]-X-
C-X2-[D/E] motif. NO moiety is transferred from
iNOS to S100A9 Cys3 and then to cysteine in the
target motif (left); or to other accessible cysteine
residues in the absence of S100A8 (right).
(B) LDLox/IFN-g induces iNOS expression, iNOS-
S100A8/A9 complex assembly, and target-selec-
tive S-nitrosylation, which causes GAIT pathway
dysregulation, and is likely to influence other
myeloid cell functions.and 90 other candidates. Interestingly, nNOS S-nitrosylates
PSD-95 at Cys3 and Cys5 (Ho et al., 2011), but their role in
NMDAR S-nitrosylation, and the possible function of PSD-95
as an nNOS-associated S-nitrosylase, has not been determined.
Despite considerable effort, a specific consensus sequence or
motif that directs S-nitrosylation globally or in an ensemble of
proteins has not been identified (Doulias et al., 2010; Marino
and Gladyshev, 2010; Seth and Stamler, 2011). The difficulty of
deconvolving the signal of a dominant motif from a multitude of
sequences targeted by diverse S-nitrosylases and adaptors
has rendered this problem nearly insoluble. The complexity of
the problem is multiplied further by the diminished specificity
of S-nitrosylation by chemical NO donors that that can generate
up to 1000 SNO-proteins. We took advantage of an analysis of
a select family of SNO-proteins, revealed by proteomic analysis
and experimentally validated to be specifically S-nitrosylated
by the iNOS-S100A8/A9 complex. A consensus I/L-X-C-X2-D/E
motif was observed in five S-nitrosylated proteins. Disruption
of conserved residues I/L and/or D/E in the motif blocked
S-nitrosylation in both proteins tested at the predicted sites,Cell 159, 623–634Cys247 of GAPDH and Cys117 of moesin.
Mutation of amino acids in the consensus
motif did not inhibit S-nitrosylation of
GAPDH Cys247 by GSNO, consistent
with previous reports of lack of specificity
of GAPDH S-nitrosylation by GSNO
(Paige et al., 2008; Wu et al., 2011). Exog-
enous, nonenzymatic donors induce high,
nonphysiological intracellular NO con-
centrations, that can direct nonselective
S-nitrosylation of free, surface-accessible
cysteine residues. The dissimilar, site-
specific S-nitrosylation of GAPDH at
Cys152 by apoptotic agonists suggests
the activity of a distinct S-nitrosylase
and cognate motif (Hara et al., 2005).
Certainly, the I/L-X-C-X2-D/E motif is not
required for all, or even most site-selec-
tive protein nitrosylations, as exemplified
by apoptosis-driven stimulation of S-
nitrosylation of GAPDH Cys152, which is
not located within the consensus motif.
More interestingly, HSPA5 is subject toLDLox/IFN-g-stimulated S-nitrosylation but neither of the two
cysteine residues are contained within the consensus motif,
and the modification requires iNOS, but not S100A8/A9. This
result indicates that a single stimulatory condition, i.e., LDLox/
IFN-g, can activate site-selective S-nitrosylation by multiple
mechanisms.
Several structural factors have been suggested to contribute
to protein S-nitrosylation, including acid-base sequences in res-
idues within 6–8 A˚ (Marino and Gladyshev, 2010), nearby hydro-
phobic residues (Seth and Stamler, 2011), high nucleophilicity
(Hess et al., 2005), helical structure, and solvent accessibility
(Doulias et al., 2010). Interestingly, the I/L-X-C-X2-D/E motif
described here exhibits most, if not all, of these characteristics.
The Cys residue is surrounded by a nearby acidic residue, D/E,
and a hydrophobic residue, I/L, which can increase cysteine
nucleophilicity. In addition, according to X-ray crystal structures,
theS-nitrosylated cysteine in each of the validated SNO-proteins
is solvent-accessible and located within or adjacent to a-helical
domains (Edwards and Keep, 2001; Huber et al., 1992; Nicolet
et al., 2010; Smith et al., 2003). The I/L-X-C-X2-D/E motif is, October 23, 2014 ª2014 Elsevier Inc. 631
present in 19 additional candidate SNO-proteins revealed by our
proteomic analysis (Table S2), suggesting a wide-ranging role in
S-nitrosylation. Ontologic analysis of motif-bearing candidates
suggests linkage to cytoskeleton organization, cell movement,
catabolic processes, inflammation, and protein localization
(Huang et al., 2009). Analysis of a SNO-protein database that
includes 810 SNO-peptides in 445 human proteins (Lee et al.,
2012) revealed only 15 peptides in 15 proteins contain the I/L-
X-C-X2-D/E motif. This result is consistent with a relatively high
specificity and low occurrence of nitrosylation by the iNOS-
S100A8/A9 complex compared to chemical NO donors.
S100A9, in the absence of S100A8, has the potential to increase
the target range by recognition of a less stringent CX2D/E motif
(Figures 6B and 6H). However, this situation may not be physio-
logically relevant because S100A9 by itself is unstable (Riva
et al., 2013). Likewise, rapid turnover of S100A8 in S100A9 null
mice suggests heterodimer formation is important to maintain
expression and function of the complex (Hobbs et al., 2003).
S100A8 and S100A9 are constitutively expressed in myeloid
cells and predominantly found as a heterodimeric complex
in vivo. S100A8/A9 comprises1%of total protein inmonocytes
attesting to its potential pathophysiological significance (Edge-
worth et al., 1991). S100A8/A9 is generally considered to be a
proinflammatory agent, however, the specific cellular functions
of S100A8/A9 are incompletely understood (Goyette and Geczy,
2011; Roth et al., 2003). Release of S100A8/A9 by activated
neutrophils, monocytes, and platelets has led to a primary focus
on the extracellular functions. Its plasma level in humans is asso-
ciated with increased risk for CVD (Ma et al., 2012; Nagareddy
et al., 2013), possibly by contributing to both innate and adaptive
immune responses. The complex is particularly abundant in
inflammatory sites, including atherosclerotic lesions of mice
and humans, and its level correlates with characteristics or
rupture-prone plaques (Croce et al., 2009; Ionita et al., 2009;
McCormick et al., 2005). Genetic deletion of S100A9 decreases
atherosclerotic lesion formation in apoE/ mice (Croce et al.,
2009). Possibly, S100A9 depletion restores GAIT system activity
by blocking GAPDH Cys247 S-nitrosylation and L13a degrada-
tion thereby suppressing expression of inflammation-related
proteins. However, the stimulatory role of S100A8/A9 in athero-
sclerotic lesion formation has not been uniformly observed in
othermousemodels (Averill et al., 2011; Croce et al., 2009). Inter-
estingly, both S100A9 and iNOS are enriched in macrophage-
rich regions in the Alzheimer’s disease (AD) brain, and depletion
of either provides significant clinical benefits in animal models
of AD (Ha et al., 2010; Nathan et al., 2005). Recent studies of
differential protein S-nitrosylation revealed 45 AD-associated
SNO-proteins in humans and 33 in mouse models of AD (Zahid
et al., 2014; Zare˛ba-Kozio1 et al., 2014). Interestingly, six human
and six mouse AD-associated SNO-proteins contain the I/L-X-
C-X2-D/E motif.
The intracellular activities of S100A8/A9, and particularly their
potential contributions to cellular inflammation remain largely
unexplored. S100A8/A9 may contribute to myeloid cell inflam-
mation via S-nitrosylation of inflammatory mediators in addition
to GAPDH. Several candidate or validated SNO-proteins re-
vealed by our analysis are linked to myeloid cell inflammatory
processes, such as CAP1 (Lee et al., 2014) and SAMHD1 (Lagu-632 Cell 159, 623–634, October 23, 2014 ª2014 Elsevier Inc.ette et al., 2011). Moreover, S100A8/A9 has been implicated in
additional intracellular functions, including cytoskeleton organi-
zation (Vogl et al., 2004) and gene regulation (Schonthaler
et al., 2013). Our discovery of an inflammatory stimulus-depen-
dent S-nitrosylase complex, and its recognition motif, opens a
new avenue of thought in deciphering the role of S-nitrosylation
in inflammation, the specific participants, and the underlying
molecular mechanisms.
EXPERIMENTAL PROCEDURES
For additional details, see Extended Experimental Procedures.
Primary Cells
Primary human PBM were isolated from healthy donors under a Cleveland
Clinic Institutional Review Board-approved protocol that adhered to American
Association of Blood Bank guidelines (Jia et al., 2012). Bone marrow-derived
macrophages (BMDM) were harvested and cultured from femurs of wild-
type or iNOS/ mice in C57BL/6J background (Jackson Laboratory, Bar
Harbor) under a protocol approved by the Cleveland Clinic Institutional
Animal Care and Use Committee. More details are described in the Extended
Experimental Procedures.
Biotin-Switch and Protein S-Nitrosylation Assay
Cell lysates (1 mg protein) were subjected to biotin-switch labeling as
described (Jia et al., 2012) by using S-nitrosylated Protein Detection Kit
(Cayman). In vitro transnitrosylase activity of S100A9 was determined as
described (Kornberg et al., 2010). Purified S100A9 protein was incubated
with 100 mMGSH control or GSNO in the dark for 30 min at room temperature.
After desalting, S100A9 was incubated with purified GAPDH for additional
30 min and then subjected to biotin-switch analysis.
S100A8-GAPDH Interaction Experiments
S100A8-GAPDH interaction was determined in vitro using His Protein Interac-
tion Pull-down Kit (Pierce). His-S100A8 and His- WHEP-R1 were expressed in
Escherichia coli and purified. His-protein (1 nmol) was immobilized on cobalt
agarose resin and then incubated with 2-fold molar excess of purified GAPDH
for 1 hr. Eluted protein was subjected to electrophoresis and immunoblot
analysis.
The FeBABE (Fe(III) (s)-1-(p-bromoacetamidobenzyl) EDTA) ‘‘artificial prote-
ase’’ method was used for mapping S100A8 interacting sites on GAPDH.
The sole cysteine in S100A8, Cys42, was mutated to serine, and additional
cysteine was introduced into S100A8 at ten amino acid intervals for covalent
labeling with FeBABE and the proteins expressed in E. coli and purified.
S100A8 (10 nmol) was labeled using FeBABE Protein Interaction Mapping
Kit (Pierce) according to manufacture’s protocol. HA-GAPDH (50 pmol) was
mixed with equimolar FeBABE-labeled S100A8 for 1 hr and subjected to
FeBABE-directed, hydroxyl radical-mediated cleavage mapping. Samples
were immediately subjected to electrophoresis and IB with anti-HA tag anti-
body. Cleavage sites were determined within eight to ten residues by deter-
mining the molecular weight of GAPDH fragments based on standard protein
markers as described (Chen and Hahn, 2003).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, two
figures, and two tables and can be found with this article online at http://dx.
doi.org/10.1016/j.cell.2014.09.032.
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